Duchenne muscular dystrophy: current knowledge, treatment, and future prospects.

Abstract

The cloning of the dystrophin gene has led to major advances in the understanding of the molecular genetic basis of Duchenne, Becker, and other muscular dystrophies associated with mutations in genes encoding members of the dystrophin-associated glycoprotein complex. The recent introduction of pharmaceutical agents such as prednisone has shown great promise in delaying the progression of Duchenne muscular dystrophy but there remains a need to develop more long-term therapeutic interventions. Knowledge of the nature of the dystrophin gene and the glycoprotein complex has led many researchers to think that somatic gene replacement represents the most promising approach to treatment. The potential use of this strategy has been shown in the mdx mouse model of Duchenne muscular dystrophy, where germ line gene transfer of either a full-length or a smaller Becker-type dystrophin minigene prevents necrosis and restores normal muscle function.

• Authors: W Douglas Biggar, Henry J Klamut, Paula C Demacio, Daniel J Stevens, Peter N Ray
• Journal: Clinical orthopaedics and related research (Clin Orthop Relat Res) Issue 401 Pg. 88-106 (Aug 2002) ISSN: 0009-921X [Print] United States
• PMID: 12151886 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Cytoskeletal Proteins
• Dystrophin

Topics

• Animals
• Cell Transplantation
• Cytoskeletal Proteins (physiology)
• Dystrophin (genetics, physiology)
• Genetic Therapy
• Humans
• Male
• Muscle, Skeletal (cytology, physiopathology, transplantation)
• Muscular Dystrophy, Duchenne (diagnosis, genetics, physiopathology, therapy)